Point72 Asset Management’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.07M Sell
55,303
-1,877,587
-97% -$101M ﹤0.01% 2029
2025
Q4
$93.7M Sell
1,932,890
-332,638
-15% -$13M 0.1% 199
2025
Q3
$69.4M Sell
2,265,528
-209,346
-8% -$4.8M 0.12% 195
2025
Q2
$54.9M Buy
2,474,874
+106,504
+4% +$2.23M 0.11% 231
2025
Q1
$44M Buy
+2,368,370
New +$39.5M 0.1% 239
2024
Q4
Sell
-54,200
Closed -$1.82M 2060
2024
Q3
$1.82M Buy
54,200
+36,300
+203% +$1.24M ﹤0.01% 1230
2024
Q2
$449K Sell
17,900
-846,200
-98% -$19.7M ﹤0.01% 1466
2024
Q1
$19.5M Buy
864,100
+75,555
+10% +$1.79M 0.05% 461
2023
Q4
$16.9M Sell
788,545
-2,655
-0.3% -$45.8K 0.04% 490
2023
Q3
$14.2M Sell
791,200
-668,709
-46% -$12.8M 0.04% 517
2023
Q2
$29.7M Sell
1,459,909
-221,238
-13% -$4.49M 0.09% 282
2023
Q1
$36.6M Sell
1,681,147
-443,053
-21% -$10.8M 0.11% 220
2022
Q4
$65.8M Sell
2,124,200
-402,000
-16% -$11.4M 0.22% 113
2022
Q3
$64.4M Buy
2,526,200
+1,674,400
+197% +$39.2M 0.26% 99
2022
Q2
$17.3M Sell
851,800
-465,800
-35% -$10.3M 0.07% 351
2022
Q1
$32.6M Buy
1,317,600
+1,060,455
+412% +$32.1M 0.13% 211
2021
Q4
$8.94M Buy
+257,145
New +$8.15M 0.04% 541
2021
Q1
Sell
-760,300
Closed -$16.3M 944
2020
Q4
$16.3M Buy
+760,300
New +$18.5M 0.08% 325
2020
Q3
Sell
-210,886
Closed -$4.71M 910
2020
Q2
$4.71M Buy
+210,886
New +$3.86M 0.03% 494
2020
Q1
Sell
-25,900
Closed -$421K 766
2019
Q4
$421K Buy
+25,900
New +$613K ﹤0.01% 788
2019
Q2
Sell
-33,600
Closed -$2.45M 1321
2019
Q1
$2.45M Buy
+33,600
New +$2.32M 0.01% 679

Other funds holding ANAB

Point72 Asset Management's ANAB Position: Q1 2026 in Review

Point72 Asset Management reduced its AnaptysBio (ANAB) stake by 97% in Q1 2026, selling an estimated $101M and leaving 55,303 shares worth $3.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Point72 Asset Management first reported a position in ANAB in Q1 2019 and has held it in 21 quarters since. The position peaked at $93.7M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Point72 Asset Management held 55,303 shares of AnaptysBio worth $3.07M as of Q1 2026.
  • Point72 Asset Management sold 1,877,587 AnaptysBio shares in Q1 2026, an estimated $101M.
  • AnaptysBio made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2029 holding.
  • Point72 Asset Management first reported a position in AnaptysBio in Q1 2019 and has held it in 21 quarters since.
  • Point72 Asset Management's AnaptysBio position peaked at $93.7M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.